CTTH CTT PHARMACEUTICAL HOLDINGS, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1035422 · Fiscal year ends 12/31
Financial factors as of 2015-09-30 (2015Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,345.6%
TTM EPS YoY-500.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-207.0%
ROA-146.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets20.0%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.17x
Accruals ratio-121.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20142014-12-31 | FY20132013-12-31 | FY20122012-12-31 | FY20112011-12-31 | FY20102010-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| SG&A expense | $17,641 | $3,844 | $158,353 | $316,408 | $309,474 |
| Operating income | -$672,162 | -$18,911 | -$1.19M | -$757,935 | -$2.07M |
| Net income | -$672,162 | -$18,911 | -$1.00M | $3.74M | -$1.10M |
| EBITDA | — | — | — | -$757,935 | -$2.00M |
| EPS (basic) | -0.04 | -0.01 | -0.11 | 0.42 | -0.13 |
| EPS (diluted) | -0.04 | -0.01 | -0.11 | 0.40 | -0.13 |
| Weighted avg. shares (diluted) | 16.34M | 14.92M | 9.41M | 9.49M | 8.47M |
| Balance sheet | |||||
| Cash & equivalents | $81,179 | $0 | $0 | $569,378 | $46,191 |
| Short-term investments | — | $0 | $164,333 | $0 | — |
| Receivables | $5,430 | $0 | $8,716 | $151 | $165,854 |
| Current assets | $1.05M | $6,252 | $203,079 | $750,734 | $519,662 |
| PP&E, net | — | — | — | $0 | $426,396 |
| Total assets | $1.66M | $0 | $203,079 | $4.18M | $1.26M |
| Current liabilities | — | $249,378 | $589,413 | $3.73M | $944,712 |
| Total liabilities | $169,490 | $29,322 | $589,413 | $3.73M | $1.26M |
| Shareholders' equity | $1.49M | -$29,322 | -$20,000 | $456,450 | $1,346 |
| Shares outstanding | 19.51M | 14.92M | 9.30M | 9.30M | 163.25M |
| Cash flow statement | |||||
| Operating cash flow | -$72,250 | -$209 | -$1.03M | -$316,132 | -$1.67M |
| Investing cash flow | $151,891 | $124,961 | $435,974 | $877,007 | $0 |
| Financing cash flow | — | $0 | $33,750 | -$37,688 | $1.45M |
| Depreciation & amortization | — | — | — | $0 | $70,365 |
| Stock-based compensation | $308,439 | $0 | $42,268 | $155,396 | $154,408 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.